Applications of Focused Ultrasound for the Treatment of Glioblastoma: A New Frontier.
Authors: Hersh AM, Bhimreddy M, Weber-Levine C, Jiang K, Alomari S, Theodore N, Manbachi A, Tyler BM
Glioblastoma (GBM) is an aggressive primary astrocytoma associated with short overall survival. Treatment for GBM primarily consists of maximal safe surgical resection, radiation therapy, and chemotherapy using temozolomide. Nonetheless, recurrence and tumor progression is the norm, driven by tumor stem cell activity and a high mutational burden. Focused ultrasound (FUS) has shown promising results in preclinical and clinical trials for treatment of GBM and has received regulatory approval for the treatment of other neoplasms. Here, we review the range of applications for FUS in the treatment of GBM, which depend on parameters, including frequency, power, pulse duration, and duty cycle. Low-intensity FUS can be used to transiently open the blood-brain barrier (BBB), which restricts diffusion of most macromolecules and therapeutic agents into the brain. Under guidance from magnetic resonance imaging, the BBB can be targeted in a precise location to permit diffusion of molecules only at the vicinity of the tumor, preventing side effects to healthy tissue. BBB opening can also be used to improve detection of cell-free tumor DNA with liquid biopsies, allowing non-invasive diagnosis and identification of molecular mutations. High-intensity FUS can cause tumor ablation via a hyperthermic effect. Additionally, FUS can stimulate immunological attack of tumor cells, can activate sonosensitizers to exert cytotoxic effects on tumor tissue, and can sensitize tumors to radiation therapy. Finally, another mechanism under investigation, known as histotripsy, produces tumor ablation via acoustic cavitation rather than thermal effects.
Introduction
Purpose
Drug delivery with BBB opening
Study Objective
To review and summarize the range of focused ultrasound (FUS) applications, mechanisms, and clinical feasibility for treating glioblastoma, including blood–brain barrier opening, tumor ablation, immunomodulation, sonodynamic therapy, and radiosensitization.
Animal model / Human subject
None — review article; no experimental organism reported
Disease model
Glioblastoma (GBM)
MRI or image guidance method
Magnetic resonance imaging (MRI) guidance
Targeted brain region(s)
Glioblastoma (Gbm) Tumor Tissue
Cargo name and characteristics
Focused ultrasound (FUS) — a non‑pharmacologic physical energy modality delivered transcranially and tightly focused on intracranial targets. Characteristics: can be applied at low intensity to transiently and locally open the blood–brain barrier (non‑ablative, reversible, MRI‑guided), at high intensity to induce thermal ablation of tumor tissue (hyperthermic necrosis), and as histotripsy to produce mechanical/cavitation‑based tissue fractionation (non‑thermal). FUS can also activate sonosensitizers and potentiate immunologic or radiosensitizing effects; parameters include frequency, power, pulse duration, and duty cycle enabling spatially precise, noninvasive treatment.
Route of administration
Intravenous (systemic) delivery across the blood–brain barrier following focused ultrasound–mediated BBB opening.
Outcomes and Safety
Summary of Outcomes
Focused ultrasound (FUS) transiently opens the blood–brain barrier to enhance drug delivery and liquid biopsy detection, can ablate glioblastoma tissue via thermal or cavitation mechanisms, and can stimulate immune responses and radiosensitize tumors to improve therapeutic efficacy.
Safety-related matter
The feasibility and safety of transcranial FUS has been demonstrated in animal models and clinical trials, and MRI guidance can target treatment precisely to limit side effects to healthy tissue.
Brain Region
Ultrasound Parameters
Ultrasound instrument
None.
FUS Frequency
None.
FUS Mode
pulsed
We are open to feedback. If you see a mistake or have a suggestion, please contact us.
← Back to Search